Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer

Status: Closed to Accrual

Learn more:

• clinicaltrials.gov: #NCT03451331
• News release

Funding for this study is provided by Bristol-Myers Squibb Company.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.